

# **Egyptian Herbal Monograph**

## **Volume 3**

### **Medicinal Plants used in Egypt**

**Egyptian Drug Authority (EDA)**

**2024**



# Egyptian Herbal Monograph

## Medicinal Plants Used in Egypt

*Vitis vinifera* L.

العنب

### 1. Names & Synonyms

*Vitis vinifera* L

**Family:** Vitaceae

**Syn.:** *Cissus vinifera* (L.) Kuntze (1)

**Arabic:** Al Inab العنب

**English:** Grapevine (2, 3), Grape (4, 5).

### 2. Parts used for medicinal purpose

Leaves and seeds (2, 6).

### 3. Major chemical constituents

#### Seeds:

- **Phenolics:** Catechin, epicatechin, procyanidins (7, 8); **phenolic acids:** gallic, caffeic, coumaric, coumaric, ferulic and fertaric acids and **flavonoids:** rutin, quercetin-3- $\beta$ -D-glucoside, quercitrin and myricetin (9, 10).
- **Fatty acids:** Linoleic acid (9).
- **Others:** Proanthocyanidins, stilbenes (10), carbohydrates, proteins and vitamin C (9).

#### Leaves:

- **Phenolics: Condensed tannin:** gallocatechins, catechins, procyanidins, procyanidin B1, procyanidin A1 and epicatechins (10, 12); **phenolic acids:** gallic, vanillic, syringic (10), caftaric, caffeic, and fertaric acids; **flavonoids:** quercetin, quercetin-3-O-glucoside, kaempferol, and myricetin (10), apigenin-7-O-glucoside, luteolin-7-O-glucoside (10), taxifolin, naringenin, hesperetin (10) and anthocyanins (10); **coumarins:** aesculin, fraxin, aesculutin and umbelliferone (10,11); **stilbenes:** monomeric, dimeric, trimeric and tetrameric derivatives (10).
- **Others:** Quinic acid (10).

#### 4. Medicinal uses (Indications)

- A. Treatment of chronic venous insufficiency, which is characterised by swollen legs, varicose veins, feeling of heaviness, pain, tiredness, itching, tension and cramps in the calves (2, 6, 13).
- B. For symptomatic relief of itching and burning associated with haemorrhoids after serious conditions have been excluded by a medical doctor (2).

#### 5. Herbal preparations correlated to medicinal use

- 1. Comminuted herbal substance as decoction or infusion (2).
- 2. Powdered herbal substance (2).
- 3. Dry extract, extraction solvent water.
  - 3.1 Leaves (2).
  - 3.2 Seeds (6).
- 4. Soft extract of leaves, extraction solvent water (2).

Herbal preparations (2-4) are in pharmaceutical dosage forms. The pharmaceutical form should be described by the pharmacopoeia full standard term.

#### 6. Posology and method of administration correlated to medicinal use

##### Preparation 1

##### Indications A and B

**Adults and elderly:** 5 - 10 g of dried leaves in 250 ml of boiling water as an infusion, 2 times daily (2).

##### Duration of use: (2)

The recommended duration of use for indication A is 4 weeks and for indication B is one week. If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a pharmacist should be consulted.

**Method of administration:** Oral use (2).

**Preparation 2****Indications A and B**

**Adults and elderly:** 270 - 350 mg, 3-5 times daily (2).

**Duration of use (2)**

The recommended duration of use for indication A is 4 weeks and for indication B is one week. If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a pharmacist should be consulted.

**Method of administration:** Oral use (2).

**Preparation 3****Indication A**

**3.1. Adults and elderly:** Single dose: 360 - 720 mg, daily dose: 360 - 720 mg (2).

**3.2. Adults and elderly:** 150 - 475 mg, daily (6).

75 – 600 mg seed extract (or pycnogenol) daily, up to 3 weeks (4).

**Duration of use**

The recommended duration of use is 12 weeks. 2-3 weeks of treatment may be required before beneficial effects are observed for leaves (2) and 4 weeks for seeds (4). Long term use is possible in consultation with a doctor (2, 6).

**Method of administration:** Oral use (2).

**Preparation 4****Indication A**

**Adults and elderly:** Soft extract in a cream base (10 g contain 282 mg soft extract). Apply a thin layer on the affected area, 1 - 3 times daily (2).

**Duration of use (2)**

The recommended duration of use is 4 weeks. If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a pharmacist should be consulted.

**Method of administration:** Cutaneous use (2).

## 7. Contraindications

Hypersensitivity to active substances and to other plants of the same family.

## 8. Special warnings and precautions for use

- If the symptoms worsen during the use of the medicinal product, a doctor or a pharmacist should be consulted.
- The use in children and adolescents below 18 years of age is not recommended (2, 6, 13).
- If there is inflammation of the skin, thrombophlebitis or subcutaneous induration, severe pain, ulcers, sudden swelling of one or both legs, cardiac or renal insufficiency, a doctor should be consulted (2, 13).
- In case of inadequate or unsatisfactory symptomatic response to the treatment of chronic venous insufficiency within 2 weeks a doctor should be consulted as oedema may have alternative causes (2).
- In case of inadequate or unsatisfactory symptomatic response within 1 week or if rectal bleeding occurs during the treatment of haemorrhoids, a doctor should be consulted (2).
- Cutaneous use: The product should not be used on broken skin, around the eyes or on mucous membranes (2).

## 9. Interactions with other medicinal products and other forms of interaction

Not known.

## 10. Fertility, pregnancy and lactation

- Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended (2, 13).
- No fertility data available.

## 11. Effects on ability to drive and use machines

No studies on the effect on the ability to drive and use machines have been performed.

## 12. Undesirable effects

- If adverse reactions occur, a doctor or a pharmacist should be consulted.
- **Grape seed:** Dizziness, nausea, anorexia and Rash (13).
- **Grape leaves:** Hypersensitivity reactions of the skin (itching and erythema, urticaria), nausea, gastrointestinal complaints and headache may occur (2).



### **13. Overdose**

No case of overdose has been reported.

### **14. Relevant biological activities**

Not required as per Egyptian guidelines for registration of herbal medicines.

### **15. Additional Information**

-

### **16. Date of compilation/last revision**

23/8/2022.

## References

1	<a href="https://powo.science.kew.org">https://powo.science.kew.org</a>
2	European Union Herbal Monograph on <i>Vitis vinifera</i> (L.) Kuntze. (2017). EMA/HMPC/424583/2016. Committee on Herbal Medicinal Products (HMPC).
3	Edwards, S. E., Rocha, I. D. C., Williamson, E. M. and Heinrich, M. (2015). <i>Phytopharmacy: An Evidence-Based Guide to Herbal Medicinal Products</i> . 1 <sup>st</sup> edition. John Wiley & Sons, Ltd.
4	Duke, J. A. (2002). <i>Handbook of Medicinal Herbs</i> . CRC Press, 2 <sup>nd</sup> edition, ISBN 9780849312847.
5	<a href="http://www.herbalgram.org">www.herbalgram.org</a>
6	Natural Health Product, <i>Vitis vinifera</i> (L.) Kuntze. (2018). Health Canada, <a href="http://webprod.hc-sc.gc.ca/nhp/ndp/nhp/monoReq.do?id=110&amp;lang=eng">http://webprod.hc-sc.gc.ca/nhp/ndp/nhp/monoReq.do?id=110&amp;lang=eng</a>
7	Spranger, I., Sun, B., Mateus, A. M., Freitas, V. and Ricardo-da-Silva, J. M. (2008). Chemical characterization and antioxidant activities of oligomeric and polymeric procyanidin fractions from grape seeds. <i>Food Chem.</i> , <b>108</b> , 519–532.
8	Furiga, A., Lonvaud-Funel, A. and Badet, C. (2009). <i>In vitro</i> study of antioxidant capacity and antibacterial activity on oral anaerobes of a grape seed extract. <i>Food Chem.</i> , <b>113</b> , 1037–1040.
9	Yalcin, H., Kavuncoglu, H., Ekici, L. and Sagdic, O. (2017). Determination of fatty acid composition, volatile components, physico-chemical and bioactive properties of grape ( <i>Vitis vinifera</i> ) seed and seed oil. <i>Journal of Food Processing and Preservation</i> , <b>41</b> , e 12854.
10	Insanu, M., Karimah, H., Pramastya, H. and Fidrianny, I. (2021). Phytochemical compounds and pharmacological activities of <i>Vitis vinifera</i> L.: An updated review. <i>Biointerface Research in Applied Chemistry</i> , <b>11</b> (5), 13829 – 13849.
11	Goufo, P., Singh, R. K. and Cortez, I. (2020). A Reference list of phenolic compounds (including stilbenes) in Grapevine ( <i>Vitis vinifera</i> L.) roots, woods, canes, stems, and leaves. <i>Antioxidants</i> , <b>9</b> (5), 398. doi: 10.3390/antiox9050398.
12	Aouey, B., Samet, A. M., Fetoui, H., Simmonds, M. S. J. and Bouaziz, M. (2016). Anti-oxidant, anti-inflammatory, analgesic and antipyretic activities of grapevine leaf extract ( <i>Vitis vinifera</i> ) in mice and identification of its active constituents by LC–MS/MS analyses. <i>Biomedicine &amp; Pharmacotherapy</i> , <b>84</b> , 1088–1098. <a href="https://doi.org/10.1016/j.biopha.2016.10.033">https://doi.org/10.1016/j.biopha.2016.10.033</a> .
13	Skidmore-Roth, L. <i>Mosby's Handbook of Herbs and Natural Supplements</i> (2010). 4 <sup>th</sup> ed., ISBN: 978-0-323-05741-7.